LENZ Therapeutics, Inc. 8-K

What Happened

• On March 24, 2026, LENZ Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025 by issuing a press release. The company furnished the press release as Exhibit 99.1 to an SEC Form 8‑K under Item 2.02 (Results of Operations and Financial Condition). The filing is signed by Daniel Chevallard, Chief Financial Officer.

Key Details

• Filing date: March 24, 2026 (Form 8‑K, Item 2.02).
• Reporting period: Fiscal year ended December 31, 2025.
• Disclosure: Press release announcing FY2025 results attached as Exhibit 99.1 and incorporated by reference.
• Signature: Form 8‑K executed by CFO Daniel Chevallard.

Why It Matters

• This 8‑K signals LENZ has publicly reported its full‑year 2025 operating and financial results; investors should review the attached press release (Exhibit 99.1) for specific figures on revenue, earnings, cash position and any management commentary.
• The announcement may contain material information that affects near‑term stock performance or investor expectations; for audited and more detailed financial statements, watch for the company’s upcoming periodic filings (e.g., Form 10‑K).